VIDEO: Belzutifan’s ‘bench to bedside journey’ for advanced clear cell renal cell carcinoma
Click Here to Manage Email Alerts
MADRID — In this video with Healio, Tian Zhang, MD, talked about “the bench-to-bedside journey of belzutifan” highlighted in the LITESPARK-005 study.
Presented at ESMO Congress, this randomized open-label phase 3 study compared belzutifan with everolimus in patients with previously treated advanced clear cell renal cell carcinoma. The results showed that patients who received belzutifan had improvements in median PFS, and the OS was “trending toward improvement,” according to Zhang, genitourinary oncologist at UT Southwestern Medical Center and member of the Kidney Cancer Association's Medical Steering Committee.
Zhang said that many patients had two or more lines of prior therapy in the front-line setting.
“It really bodes well for belzutifan as a monotherapy, even in refractory patient populations. I’m really excited to see what patient populations benefit the most,” Zhang said.
Reference:
- Albiges L, et al. Abstract LBA88. Presented at: European Society for Medical Oncology Congress; Oct. 20-24, 2023; Madrid.
Collapse
Healio Interviews
Click Here to Manage Email Alerts